Status | In progress |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 3938 |
Provisional Schedule
Final draft guidance | 08 September 2023 - 22 September 2023 |
Expected publication | 11 October 2023 |
Project Team
Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TATeam1@nice.org.uk
Stakeholders
Companies sponsors | Eli Lilly & Company |
Others | Department of Health and Social Care |
NHS England | |
Welsh Government | |
Patient carer groups | Diabetes UK |
Professional groups | Royal College of Physicians |
UK Clinical Pharmacy Association | |
Comparator companies | Boehringer Ingelheim |
Nova Nordisk | |
Sanofi | |
Pfizer | |
General commentators | All Wales Therapeutic and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare Products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
01 August 2023 | Committee meeting: 2 |
27 June 2023 - 18 July 2023 | Draft guidance |
06 June 2023 | Committee meeting: 1 |
12 April 2023 | The appraisal committee meeting will now take place on Tuesday 6 June 2023. This is to allow the company to address issues raised in the External Assessment Report. |
27 January 2023 | The appraisal committee meeting is now scheduled to take place on Wednesday 3 May 2023. This is to allow time to work through technical elements relating to the appraisal. |
07 June 2022 | Invitation to participate |
22 March 2022 - 21 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
28 January 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual